Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerResearch Summary
Analyzed using Evidence Intelligence™
Adding sitagliptin to insulin improves glycemic control in type 2 diabetes
Last updated July 5, 2026
Key finding
The difference in HbA1c reduction between the groups was 0.9% (95% confidence interval, 0.4 to 1.5, P = 0.01).
This study evaluated the efficacy and safety of adding sitagliptin to insulin treatment in patients with type 2 diabetes, finding significant reductions in HbA1c and hypoglycemia incidence.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
This study evaluated the efficacy and safety of adding sitagliptin to insulin treatment in patients with type 2 diabetes, finding significant reductions in HbA1c and hypoglycemia incidence.
Clinical relevance
These findings are clinically significant as they suggest that combining sitagliptin with insulin can enhance diabetes management, leading to better patient outcomes and potentially reducing the risk of complications associated with poorly controlled diabetes.
Keep in mind
The study's population may not represent all patients with type 2 diabetes. The trial duration was limited to 24 weeks, which may not capture long-term effects. No data on the long-term safety of sitagliptin was provided.
Published in
Journal Reference
Publication details and source links for this paper.
Seiji S, Yoshifumi S, Kinsei K, et al. Efficacy and safety of DPP-4 inhibitor added to Insulin treatment in patients with type 2 diabetes. PLOS ONE. 2015;10(3):e0121988. doi:10.1371/journal.pone.0121988
Main Effects
Adding sitagliptin to insulin reduced HbA1c from 7.9% to 7.0% (P < 0.0001).
No significant change in HbA1c was observed in the insulin-only group (P = 0.32).
Hypoglycemia incidence was significantly lower in the Ins+Sita group.
Treatment satisfaction improved in the Ins+Sita group.
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Insulin plus Sitagliptin, Insulin therapy and HbA1c, Hypoglycemia events, Treatment satisfaction.
This study contributes evidence to
Primary intervention
Insulin plus Sitagliptin
Primary outcomes
- HbA1c
- Hypoglycemia events
- Treatment satisfaction
Evidence topics
Primary intervention
Primary outcomes
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
4
Evidence pairs
4
Relationships
3
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 68
3
Related topics
4
Evidence pairs
505
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 4 evidence relationships
- Includes primary outcome data
- Linked to 3 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Add related evidence to your Evidence Tracker
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence relationship
Insulin Therapies and HbA1c
Related evidence
Evidence topic
Hypoglycemia
Save evidence
Evidence topic
HbA1c Reduction
Save evidence
Core evidence
Study findings
The primary outcomes reported in this study.
Hypoglycemia events
Insulin plus Sitagliptin → Hypoglycemia events
Insulin plus Sitagliptin → Hypoglycemia events
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerTreatment satisfaction
Insulin plus Sitagliptin → Treatment satisfaction
Insulin plus Sitagliptin → Treatment satisfaction
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- 83
- Strong
- ImpactScore™
- 90
- Very Positive
- ConsistencyScore™
- 80
- consistent
Supporting studies: Based on 5 studies
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Evidence Suggest
- Sitagliptin reduced HbA1c by 0.9% compared to insulin alone (P < 0.0001).
- No significant change in HbA1c was found in the insulin group (P = 0.32).
- The Ins+Sita group experienced fewer hypoglycemic events.
Who this applies to
- Adults with type 2 diabetes currently on insulin therapy.
- Patients seeking improved glycemic control and reduced hypoglycemia.
Keep in Mind
- Results may not apply to all demographics of type 2 diabetes patients.
- The study's short duration limits understanding of long-term effects.
- Further research is needed to confirm these findings in larger populations.
Between the Lines
- The study's population may not represent all patients with type 2 diabetes.
- The trial duration was limited to 24 weeks, which may not capture long-term effects.
- No data on the long-term safety of sitagliptin was provided.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Insulin Therapies and HbA1c, Insulin Therapies and Hypoglycemia.
Related evidence relationships
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
Insulin Therapies → HbA1c
Medications
Evidence Intelligence™
- EvidenceScore™
- 83
- Strong
- ImpactScore™
- 90
- Very Positive
- ConsistencyScore™
- 80
- consistent
Supporting studies: Based on 5 studies
View evidenceMedications
Insulin Therapies → Hypoglycemia
Medications
Evidence Intelligence™
- EvidenceScore™
- Strong
- Score 79 · Based on 3 studies
- ImpactScore™
- 67
- Slightly Positive
- ConsistencyScore™
- 35
- mixed
Supporting studies: Based on 3 studies
View evidenceIncluded in these evidence collections
Curated evidence collections and hubs this study is part of.
HbA1c Evidence Hub
All studies measuring HbA1c
5 studies
outcome_hubMeasures HbA1c as a key outcome.
Insulin Therapies Evidence Hub
All studies on Insulin Therapies
5 studies
intervention_hubContributes to Insulin Therapies evidence base.
Hypoglycemia Evidence Hub
All studies measuring Hypoglycemia
3 studies
outcome_hubMeasures Hypoglycemia as a key outcome.
Explore more in Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on Insulin therapy and HbA1c
Intervention: Insulin therapyOutcome: HbA1c
5 results
All studies on Insulin therapy and Hypoglycemia events
Intervention: Insulin therapyOutcome: Hypoglycemia events
3 results
All studies on Insulin therapy
Intervention: Insulin therapy
5 results
All studies measuring HbA1c
Outcome: HbA1c
5 results
All studies measuring Hypoglycemia events
Outcome: Hypoglycemia events
3 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does Insulin Therapies improve HbA1c?
Strong Evidence
Insulin Therapies may improve HbA1c.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 83.4 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 14 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does Insulin plus Sitagliptin improve HbA1c?
Emerging Evidence
Insulin plus Sitagliptin appears to improve HbA1c.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Does Insulin plus Sitagliptin affect hypoglycemia events?
Emerging Evidence
Insulin plus Sitagliptin appears to improve Hypoglycemia events.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Hypoglycemia events
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Does Insulin plus Sitagliptin improve treatment satisfaction?
Emerging Evidence
Insulin plus Sitagliptin appears to improve Treatment satisfaction.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Treatment satisfaction
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
Semaglutide with Insulin Improves Diabetes Control and Kidney HealthQCC Model Enhances Diabetes ManagementVildagliptin improves glycemic control in type 2 diabetes patients on insulinArtificial pancreas may improve glucose control in type 1 diabetesHybrid Closed-Loop Insulin Improves Glycemic Control in Youth
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.